United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

A panel of independent experts is meeting today to evaluate Pfizer's coronavirus vaccine. By day's end, they're expected to come to a vote that will advise the US Food and Drug Administration (FDA) to approve or deny the shot for emergency use.  But FDA Commissioner Dr. Stephen Hahn said the outcome is already predictable, and that the agency intends to act on the advisory panel's advice immediately. 

FDA director: The agency expects to approve Pfizer's vaccine after today's crucial hearing

The feds will likely scrutinize recent allergic reactions to Pfizer's coronavirus vaccine before clearing it for emergency use, the government's top vaccine adviser said. Two people who received the groundbreaking COVID-19 shot in the UK suffered severe allergic reactions to it, leading British health officials to warn that individuals with “significant” allergic reactions may not.

FDA likely to weigh allergic reactions of Pfizer's COVID-19 vaccine

APA Corporation

Chevron

Devon Energy

Diamondback Energy

Marathon Oil

Occidental Petroleum

The top gainers of the S&P 500 during the past month are all energy firms - Occidental Petroleum (OXY), Apache (APA), Diamondback Energy (FANG), Marathon Oil (MRO) and Devon Energy (DVN).

Vaccine Euphoria Aids Oil in the Face of Huge Supply Build

A FDA panel is scheduled to vote Thursday on whether to recommend the approval of Pfizer and BioNTech's coronavirus vaccine for emergency use.

6 things to know before FDA panel votes on Pfizer's Covid vaccine today

A Food and Drug Administration panel will meet Thursday to discuss Pfizer's BioNTech-partnered coronavirus vaccine. The results could spark Pfizer stock and BioNTech stock.

Pfizer Stock Faces Its Next Big Covid Challenge: An FDA Committee

Novavax

Sanofi

There are plenty of catalysts on the horizon for these investments -- and a healthy dose of risk.

3 Best Biotech Stocks of 2020: Are They Buys Now?

The company has a lot more going for it than just a coronavirus vaccine.

3 Reasons to Buy Pfizer Stock Now

Documents for the Pfizer-BioNTech Covid-19 vaccine were 'unlawfully accessed' in a cyberattack on the European Medicines Agency.

Pfizer-BioNTech vaccine documents were ‘unlawfully accessed' in a cyberattack on Europe's medicines agency

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said on Wednesday that hackers illegally accessed documents related to their COVID-19 vaccine in an attack on the European Medicines Agency (EMA). What Happened: The two companies said in a statement they believe the personal data of trial participants were not compromised and that the EMA had assured them that the incident would not impact the timeline of the vaccine's review.

Pfizer, BioNTech Say Hackers Accessed COVID-19 Vaccine Development Data

It was the third authorization of BNT162b2 by a national healthcare regulator in the space of a week.

Pfizer and BioNTech's Coronavirus Vaccine Approved in Canada

Shares of BioNTech were down 0.6% and Pfizer Inc.'s stock fell 1.1% in trading on Wednesday after the companies announced that their COVID-19 vaccine candidate had received emergency authorization in Canada. This is the third country, after Bahrain and the United Kingdom, to authorize their coronavirus vaccine.

Canada authorizes BioNTech/Pfizer COVID-19 vaccine

Canada approved Pfizer and BioNTech's coronavirus vaccine for use, the country's health department announced on Wednesday. The UK made a similar decision earlier this month, but the vaccine is still awaiting authorization for emergency use in the US.  The vaccine, made by US drugmaker Pfizer and German biotech firm BioNTech, is 95% effective at preventing COVID-19, according to the company's Phase 3 trials. Pfizer predicts it will produce up to 50 million vaccine doses for global distribution by the end of 2020, and up to 1.3 billion doses in 2021.

Canada beats the US to approving Pfizer and BioNTech's coronavirus vaccine

Pfizer stock toppled Wednesday on reports of two allergic reactions after the U.K. began its widespread coronavirus vaccine campaign. Both were staff members of the National Health Service.

Pfizer Stock Trips After U.K. Notes Possible Allergic Reactions To Covid Vaccine

Both Canada and the U.K. have now approved the vaccine for emergency use. It's still under review in the U.S.

Canada Approves Pfizer's Coronavirus Vaccine

As early as next week, the Department of Defense is slated to receive nearly 44,000 of the first dose of Pfizer's coronavirus vaccine.

Pentagon reveals plans to distribute first 44,000 doses of Pfizer vaccine as early as next week

Apple

Alibaba

Bristol-Myers

CVS Health

Farfetch

Morgan Stanley

Everyone is on the hunt for undervalued stocks. Keep in mind, even more highly valued stocks can be undervalued.

7 Undervalued Stocks to Buy Now

Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag

Tuesday, the U.K. became the first country in the West to roll out a Covid-19 vaccine, administering Pfizer's vaccine less than a week after British regulators gave the go-ahead to begin mass inoculations.

U.K. Warns That People With Severe Allergic Reactions Should Not Get Covid-19 Vaccine

The U.K. began widespread vaccination Tuesday after becoming the first western country to authorize the vaccine.

U.K. Regulator Warns People With ‘Significant' Allergies To Avoid Pfizer-BioNTech Vaccine

U.K. regulators said Wednesday that people who have a "significant history'' of allergic reactions shouldn't receive the new Pfizer-BioNTech vaccine.

UK investigates possible allergic reactions to Pfizer coronavirus shot

The U.K. regulator has warned people with a history of “significant allergic reactions” not to have the Pfizer–BioNTech COVID-19 vaccine after two health-care workers had adverse reactions on the first day of the rollout.

U.K. regulators warn people with history of ‘significant' allergic reactions not to have Pfizer–BioNTech COVID-19 vaccine, after two adverse reactions

People who have a history of "significant" allergic reactions should not currently receive the coronavirus vaccine developed by Pfizer and BioNTech, the U.K. drug regulator said on Wednesday.

People with a history of 'significant' allergic reactions shouldn't have Pfizer jab, UK regulator warns

Pfizer, Inc. recently made headlines as the first pharmaceutical company to produce a successful COVID-19 vaccine. The company, along with its German partner BioNTech SE, filed for emergency-use authorization in late November.

Pfizer Is Worth The Risk For A Vaccine Payoff

AstraZeneca

Biogen

GlaxoSmithKline

Moderna

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure appeared first on InvestorPlace.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

Shares of Pfizer Inc. rose 0.5% in the extended session Tuesday after the company said the U.S. Food and Drug Administration has accepted for priority review the company's vaccine candidate against bacteria causing pneumonia and other illnesses in adults. The vaccine candidate would cover more strains of the bacteria than other vaccines in the market and in late-stage trials, the company said.

News for Pfizer Stock (PFE)